Gerard J. McGarrity, Ph.D., has accepted the position of vicepresident and director of development at Genetic Therapy Inc.McGarrity had been president of Coriell Institute for MedicalResearch in Camden, N.J. He has also been chairman of theRecombinant DNA Advisory Committee of the NationalInstitutes of Health since 1987. Genetic Therapy(NASDAQ:GTII) of Gaithersburg, Md., is developing deliverysystems for human gene therapy.

ProCyte Corp. of Kirkland, Wash., has elected Jules Blake, Ph.D.,and William M. Sullivan to its board. Blake is the former vicepresident of corporate scientific affairs for Colgate-Palmolive. Sullivan is the former chairman, president and chiefexecutive officer of Burroughs Wellcome Co. ProCyte(NASDAQ:PRCY) is developing peptide-based compounds forwound healing and tissue repair.

Alkermes Inc. has appointed Scott D. Putney, Ph.D., vicepresident of molecular biology. Putney comes to Alkermesfrom Repligen Corp., where he was vice president and directorof molecular biology. Alkermes (NASDAQ:ALKS) of Cambridge,Mass., is a neuropharmaceutical company.

Gianfranco Rutili has been named vice president ofdevelopment of Shaman Pharmaceuticals Inc. of San Carlos,Calif., developer of therapeutics from botAnical sources.

Amylin Corp. has appointed Mark Lotz director of regulatoryaffairs. Lotz was an associate director of regulatory affairs atAbbott Laboratories Inc. San Diego-based Amylin is working ontherapeutic products for diabetes, obesity and related healthproblems.

Richard A. Farkas has joined Somanetics Corp. as vicepresident responsible for operations, including research anddevelopment, production engineering, software developmentand product planning. Farkas was senior vice president oftechnology at Irwin Magnetic Systems Inc. Somanetics(NASDAQ:SMTS) is based in Troy, Mich.

Enzytech of Cambridge, Mass., has named Howard Bernstein,Ph.D., to the newly created position of vice president ofresearch. Bernstein joined the company in 1988 as a seniorresearch scientist. Enzytech is developing delivery systemsfor therapeutic proteins and peptides.

Athena Neurosciences Inc. of South San Francisco, Calif., hasappointed Steve T. Guillen director of sales and Richard A.Lukasko director of distribution. Guillen was manager of fieldmanagement development at Merck, Sharp & Dohme. Lukaskowas third-party administrator at Longs Drug Stores CaliforniaInc. Athena Neurosciences focuses on diagnostics andtherapeutics for central nervous system diseases anddisorders.

(c) 1997 American Health Consultants. All rights reserved.